JenaValve Technology has received premarket approval from the FDA for its Trilogy THV System. The system is now the first transcatheter device in the U.S. with a dedicated indication for patients ...
With its FDA approval, JenaValve intends to commence launch activity for the Trilogy System immediately with participating ...
The approval comes two months after Edwards Lifesciences scuttled plans to buy JenaValve for $945 million amid opposition from the Federal Trade Commission.
JenaValve's Trilogy System, FDA-approved for severe AR, offers secure anchoring without calcium. It is a breakthrough for ...
The FDA PMA for JenaValve's Trilogy device for TAVR-AR comes months after a court struck down Edwards Lifesciences attempt to ...
JenaValve announced today that it has received FDA premarket approval (PMA) for its Trilogy transcatheter heart valve system.
Zacks Investment Research on MSN
Edwards Lifesciences stock up 22.1% in a year: What's driving it?
Edwards Lifesciences EW has delivered an impressive return over the past year, with shares rallying 22.1%. The stock comfortably outpaced the industry’s 3.8% fall and closely tracked the S&P 500 ...
Israel’s human-centric approach to medtech has not only helped the Startup Nation to emerge as one of the world’s most innovative industry players; but it’s also drawn international attention for ...
Valcare Medical, Inc., a pioneer in transcatheter mitral valve repair solutions, today announced the appointment of two new members to its Board of Directors: Jeffrey B. Jump and Jacques Séguin, MD, ...
Overview The global Transcatheter Mitral Valve Replacement (TMVR) market is witnessing rapid expansion and is expected to grow at a strong CAGR of nearly 20% during the forecast period. The increasing ...
The "Structural Heart Devices Market - Growth, Share, Opportunities & Competitive Analysis, 2024 - 2032" report has been added to the Credence Research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results